Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Haemonetics Corporation (NYSE:HAE) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.10.

HAE has been the subject of several research reports. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. raised their price target on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a report on Friday, December 12th. Mizuho boosted their price objective on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, November 21st. Finally, CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th.

Haemonetics Trading Up 0.6%

Shares of NYSE HAE opened at $81.04 on Wednesday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a 50-day moving average of $72.67 and a two-hundred day moving average of $65.26. The company has a market cap of $3.79 billion, a PE ratio of 23.70, a P/E/G ratio of 1.52 and a beta of 0.30. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the business posted $1.12 earnings per share. Haemonetics’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP lifted its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the period. EverSource Wealth Advisors LLC increased its holdings in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its stake in Haemonetics by 59.4% in the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares during the period. Versant Capital Management Inc boosted its holdings in Haemonetics by 216.4% during the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 567 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 837 shares during the period. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.